Title:
ALBUMIN FUSION PROTEIN
Document Type and Number:
Japanese Patent JP2011217750
Kind Code:
A
Abstract:
To provide therapeutic proteins fused to albumin, or fragments or variants of the albumin.
The present invention relates to: albumin fusion proteins comprising a therapeutic protein and the albumin including a specific sequence; nucleic acid molecules encoding the albumin fusion proteins; vectors containing the nucleic acids; and host cells transformed with the nucleic acids vectors. The present invention relates to pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases using the albumin fusion proteins.
More Like This:
| JP7242611 | antibody-producing non-human mammal |
| JP2012029662 | POLYPEPTIDE |
| JP2004523527 | Mammalian tumor susceptibility gene product and its usage |
Inventors:
BALLANCE DAVID JAMES
SLEEP DARRELL
TURNER ANDREW JOHN
SADEGHI HOMAYOUN
PRIOR CHRISTOPHER P
SLEEP DARRELL
TURNER ANDREW JOHN
SADEGHI HOMAYOUN
PRIOR CHRISTOPHER P
Application Number:
JP2011109620A
Publication Date:
November 04, 2011
Filing Date:
May 16, 2011
Export Citation:
Assignee:
PRINCIPIA PHARMACEUTICAL CORP
NOVOZYMES BIOPHARMA UK LTD
NOVOZYMES BIOPHARMA UK LTD
International Classes:
C12N15/09; A61K35/12; A61K35/76; A61K38/00; A61K38/21; A61K38/22; A61K38/23; A61K38/27; A61K38/28; A61K38/43; A61K38/46; A61K38/48; A61K38/55; A61K39/395; A61K47/48; A61K48/00; A61P1/00; A61P1/04; A61P1/16; A61P1/18; A61P3/10; A61P3/14; A61P5/00; A61P5/10; A61P5/14; A61P5/40; A61P7/00; A61P7/04; A61P7/06; A61P9/00; A61P9/06; A61P9/10; A61P9/12; A61P11/00; A61P11/06; A61P13/00; A61P13/02; A61P13/08; A61P13/12; A61P15/00; A61P15/08; A61P15/10; A61P15/18; A61P17/00; A61P17/02; A61P17/06; A61P17/12; A61P17/14; A61P19/00; A61P19/02; A61P19/08; A61P19/10; A61P21/00; A61P21/04; A61P25/00; A61P25/02; A61P25/08; A61P25/16; A61P25/28; A61P27/02; A61P29/00; A61P31/00; A61P31/12; A61P31/14; A61P31/16; A61P31/18; A61P31/20; A61P31/22; A61P33/02; A61P33/06; A61P33/12; A61P35/00; A61P35/02; A61P35/04; A61P37/00; A61P37/02; A61P37/04; A61P37/06; A61P37/08; A61P39/02; A61P41/00; A61P43/00; C07K14/47; C07K14/52; C07K14/55; C07K14/56; C07K14/565; C07K14/585; C07K14/60; C07K14/61; C07K14/62; C07K14/635; C07K14/65; C07K14/705; C07K14/715; C07K14/745; C07K14/75; C07K14/76; C07K14/765; C07K14/81; C07K16/00; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N5/02; C12N5/10; C12N9/14; C12N9/74; C12N9/99; C12N15/62; A61K39/00
Domestic Patent References:
| JPH07503368A | 1995-04-13 | |||
| JP2000502901A | 2000-03-14 | |||
| JPH04506598A | 1992-11-19 | |||
| JPH11501506A | 1999-02-09 | |||
| JPH03201987A | 1991-09-03 |
Foreign References:
| WO1992014483A1 | 1992-09-03 |
Attorney, Agent or Firm:
Yusuke Hiraki
Satoshi Fujita
Ishii Teiji
Satoshi Fujita
Ishii Teiji
Previous Patent: PHAGE MICROARRAY PROFILING OF HUMORAL RESPONSE TO DISEASE
Next Patent: OPTIMIZATION OF CROSSOVER POINT FOR DIRECTED EVOLUTION
Next Patent: OPTIMIZATION OF CROSSOVER POINT FOR DIRECTED EVOLUTION